I-MOVE, influenza vaccine effectiveness

Project description

The I-MOVE (Influenza – Monitoring Vaccine Effectiveness in Europe) network aims to measure influenza vaccine effectiveness (VE) in Europe. The I-MOVE network includes a multicentre study at primary care level to measure influenza VE and a multicentre study carried out at hospital level to measure VE against severe influenza. Within the I-MOVE network we also carry out studies measuring the impact of influenza vaccination campaigns.

Context situation

The project started in 2007 and has carried out multicentre and other studies since the 2008–9 influenza season. The network consists of 29 partners including ECDC, WHO-EURO, regional and national public health institutes, hospitals, small and medium enterprises, and universities from 15 European Union/European Economic Area Member States. The I-MOVE network measures VE in a way that is scientifically and financially independent from vaccine manufacturers.

Project activities

Development of generic protocols to measure influenza vaccine effectiveness studies

test-negative design, cohort, screening method, impact studies.

Coordination of multicentre, multicountry surveillance and research networks

review of protocols, organisation of scientific conferences and technical workshops, training

Pooled analysis to provide vaccine effectiveness at European level

data management, data validation, development of scripts, report writing, scientific communication

    Scientific publications

    I-MOVE/I-MOVE+ study team, 2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.

    Kissling E, Valenciano M, Pozo F, Vilcu A-M, Reuss A, Rizzo C, et al

    Influenza Other Resp Viruses. Accepted Author Manuscript.doi:10.1111/irv.125207

    Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020.

    Rose Angela, Kissling Esther, Emborg Hanne-Dorthe, Larrauri Amparo, McMenamin Jim, Pozo Francisco, Trebbien Ramona, Mazagatos Clara, Whitaker Heather, Valenciano Marta, European IVE group

    Euro Surveill. 2020;25(10):pii=2000153.

    Available here

    Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine.

    Rose AMC, Kissling E, Gherasim A, et al.

    Influenza Other Respir Viruses. 2020 May;14(3):302-310. DOI: 10.1111/irv.12714. PMID: 32022450; PMCID: PMC7182608

    Available here

    Interim 2019/20 influenza vaccine effectiveness six European studies, September 2019 to January 2020

    Rose A, Kissling E, Emborg H-D, Larrauri A, McMenamin J, Pozo F et al.

    Euro Surveil. 2020;25(10):pii=2000153.

    Available here

    Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort. Euro Surveill. 2019;24(48):pii=1900604.

    Kissling E, Pozo F, Buda S, Vilcu A-M, Gherasim A, Brytting M, Domegan L, Gómez V, Meijer A, Lazar M, Vučina Vesna V, Dürrwald R, van der Werf S, Larrauri A, Enkirch T, O’Donnell J, Guiomar R, Hooiveld M, Petrović G, Stoian E, Penttinen P, Valenciano M, I-MOVE primary care study team

    Available here

    Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019

    Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, et al., European IVE group

    Euro Surveill.2019;24(8):pii=1900121

    Available here

    Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18).

    Kissling E, Pozo F, Buda S, Vilcu AM, Rizzo C, Gherasim A, et al.

    Vaccine X. 2019;3:100042

    Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. Euro Surveill. 2019;24(45):pii=1900268.

    Machado A, Mazagatos C, Dijkstra F, Kislaya I, Gherasim A, McDonald Scott A, Kissling E, Valenciano M, Meijer A, Hooiveld M, Nunes B, Larrauri A

    Available here

    Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

    Rondy M, Kissling E, Emborg H-D, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A,McMenamin J, Valenciano M, I-MOVE/I-MOVE+ group.

    Euro Surveill. 2018;23(9):pii=18-00086

    Available here

    Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/12-2016/17. Influenza Other Respir Viruses

    Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O Donnell J, et al, I-MOVE primary care multicentre case-control team

    2018;1-15.doi: 10.1111/irv.12562

    Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

     Kissling E, Rondy M, I-MOVE/I-MOVE+ study team.

    Euro Surveill. 2017;22(7):pii=30464.

    Available here

    Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study

    Kissling E, Valenciano M.

    Euro Surveill. 2016;21(6):pii=30134.

    Available here

    Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case–Control Study, Europe 2014/15.

    Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth J K, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz I A, Bella A, Larrauri A, Ferenczi A, O´Donell J.

    Euro Surveill. 2016;21(7):pii=30139.

    Available here

    Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?

    Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al, I-MOVE case–control study team. I-MOVE multicentre case–control study 2010/11 to 2014/15

    Euro Surveill. 2016;21(16):pii=30201

    Available here

    Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).

    Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, Pitigoi D, Machado A, Pozo F; I-MOVE Multicentre Case Control Study Team. The European I-MOVE Multicentre 2013-2014 Case-Control Study.

    Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28. PMID: 25936723

    Available here

    Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case–control study, influenza season 2012/13.

    Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen J M, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, Jiménez-Jorge S, Daviaud I, Guiomar R, O’Donnell J, Necula G, Głuchowska M, Moren A.

    Euro Surveill. 2014;19(6):pii=20701. https://doi.org/10.2807/1560-7917.ES2014.19.6.20701

    Available here

    Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case–control study, 2011/12.

    Kissling E, Valenciano M, I-MOVE case–control studies team Collective.

    Euro Surveill. 2012;17(15):pii=20146. https://doi.org/10.2807/ese.17.15.20146-en

    Available here

    I-MOVE: a European network to measure the effectiveness of influenza vaccines.

    Valenciano M, Ciancio B; I-MOVE study team

    Euro Surveill. 2012 Sep 27;17(39):20281. doi: 10.2807/ese.17.39.20281-en.

    Available here

    Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study

    Kissling E, Valenciano M; I-MOVE case-control studies team

    Euro Surveill. 2011 Mar 17;16(11):19818. doi: 10.2807/ese.16.11.19818-en.

    Available here

    Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study.

    Kissling E, Valenciano M; I-MOVE case-control studies team

    Euro Surveill. 2011 Mar 17;16(11):19818. doi: 10.2807/ese.16.11.19818-en. PMID: 21435329.

    Available here

    Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.

    Valenciano M, Kissling E, Cohen JM, et al.

    Plos Medicine. 2011 Jan;8(1):e1000388. DOI: 10.1371/journal.pmed.1000388. PMID: 21379316; PMCID: PMC3019108.

    Available here

    Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks

    Valenciano M, Kissling E, Ciancio BC, Moren A

    Vaccine. 2010 Oct 28;28(46):7381-8. doi: 10.1016/j.vaccine.2010.09.010. Epub 2010 Sep 17. PMID: 20851086

    Available here

    First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States

    Valenciano M, Ciancio B C, Moren A, the influenza vaccine effectiveness working group Collective

    Euro Surveill. 2008;13(43):pii=19015.

    Available here

    Find all our scientific publications

    Référencement Centrales d'achats

    Hébergement de données de santé

    Nous sommes Hébergeur de Données de Santé (HDS) à caractère personnel depuis 2012 avec la certification ISO 27001/HDS depuis 2019.

    En savoir plus

    Engagement et éthique

    Découvrez nos engagements et valeurs dans notre charte